Inpatient Therapy With Calcineurin Inhibitors in Severe Ulcerative Colitis

Background: Inpatient management of severe ulcerative colitis is complicated by the use of prior immunosuppressant therapies. Our aim was to determine the rate of 1-year colectomy among individuals receiving inpatient calcineurin inhibitor (CNI)-based therapy stratified by prior biologic therapy. Methods: A retrospective cohort study was performed between January 1, 2013 and April 1, 2018. Only individuals requiring inpatient administration of intravenous cyclosporine or oral tacrolimus were included in the analysis. Individuals were stratified according to prior biologic therapy exposure. The primary outcome of interest was 1-year risk of colectomy. Kaplan-Meier curves were generated for time-to-event data, and regression models were performed to examine the effects of covariates on the clinical endpoint. Results: Sixty-nine (62.3% male) patients were treated with an inpatient CNI-based therapy and were included in the analysis. Fifteen (21.7%) patients were biologic-naive, 42 (60.9%) patients had prior exposure to 1 class of biologic therapy, and 12 (17.4%) patients had prior exposure to 2 classes of biologic therapy (third-line CM therapy). Third-line CNI therapy showed a greater risk of 1-year colectomy risk when compared with the risk for patients who were biologic-naive (hazard ratio, 3.63; 95% confidence interval, 1.17-13.45; P = 0.025). In a multivariate proportional hazards model, third-line CM therapy remained significantly associated with 1-year colectomy risk (hazard ratio, 7.94; 95% confidence interval, 1.97-39.76; P = 0.003). Conclusions: The use of CM-based therapy in individuals exposed to multiple classes of prior biologic therapies leads to a significantly increased risk of 1 -year colectomy. Future studies will be required to compare inpatient management strategies with the expanding novel therapies in UC.

Automated summary

This study aimed to determine the rate of inpatient colectomy in severe ulcerative colitis patients receiving CNI-based therapy, with findings showing significantly increased risk of colectomy within 1 year for individuals exposed to multiple classes of prior biologic therapies and treated with CM-based therapy.